Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Colorectal Neoplasms, Metastases, Neoplasm
Both
Colorectal Neoplasms, Metastases, Neoplasm
Trial Information
Inclusion Criteria:
- Metastatic colorectal carcinoma
- Suitable for first-line treatment of metastatic disease
Exclusion Criteria:
- Peripheral neuropathy greater than Grade 1
- Adjuvant therapy within 6 months prior to study treatment
- Prior oxaliplatin
- Prior pelvic or whole abdomen radiation
- Any history of coronary angioplasty or history of myocardial infarction
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
D2820C00007
NCT ID:
NCT00065117
Start Date:
September 2003
Completion Date:
February 2004
Related Keywords:
- Colorectal Neoplasms
- Metastases, Neoplasm
- metastatic
- colorectal
- first-line
- adjuvant
- cancer
- Colorectal Cancer
- Colorectal Carcinoma
- Colorectal Tumors
- Neoplasms, Colorectal
- Neoplasms
- Colorectal Neoplasms
- Neoplasm Metastasis
Name | Location |
|---|---|
| Research Site | Anaheim, California |
| Research Site | Arlington Heights, Illinois |
| Research Site | Baton Rouge, Louisiana |
| Research Site | Baltimore, Maryland |
| Research Site | Branson, Missouri |
| Research Site | Albany, New York |
| Research Site | Asheville, North Carolina |
| Research Site | Allentown, Pennsylvania |
